Table 5.
Efficacy outcomes.
| Outcome | trHE | Non-trHE |
|---|---|---|
| All | n = 18 | n = 25 |
| Confirmed ORR, n (%) [95% CI] | 8 (44.4) [19.02–69.87] | 15 (60) [39.36–80.64] |
| CR | 3 (16.7) | 5 (20) |
| PR | 5 (27.8) | 10 (40) |
| SD | 9 (50) | 10 (40) |
| PD | 1 (5.6) | 0 |
| DCR | 17 (94.4) | 25 (100) |
| Median PFS, months (95% CI) | 8.0 (0–16.32) | 18.0 (4.56–31.43) |
| BRAFi | n = 3 | n = 9 |
| ORR | 1 (33.3) | 4(44.4) |
| CR | 0 | 0 |
| PR | 1 (33.3) | 4 (44.4) |
| SD | 2 (66.7) | 5 (45.6) |
| DCR | 3 (100) | 9 (100) |
| BRAFi+MEKi | n = 4 | n = 8 |
| ORR | 2 (50) | 6 (75) |
| CR | 1 (25) | 1 (12.5) |
| PR | 1 (25) | 5 (62.5) |
| SD | 2 (50) | 2 (25) |
| DCR | 4 (100) | 8 (100) |
| BRAFi+anti-PD-1 antibody | n = 11 | n = 8 |
| ORR | 5 (45.5) | 5 (62.5) |
| CR | 2 (18.1) | 4 (50) |
| PR | 3 (27.3) | 1 (12.5) |
| SD | 5 (45.5) | 3 (37.5) |
| PD | 1 (9.1) | 0 |
| DCR | 9 (90.9) | 8 (100) |
ORR, overall response rate; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; PFS, progression-free survival.